| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA645: Avelumab with axitinib for untreated advanced renal cell carcinoma |
|
Medicine details |
|
| Medicine name | avelumab (Bavencio®) |
| Formulation | 20 mg/ml concentrate for solution for infusion |
| Reference number | 3454 |
| Indication | In combination with axitinib for the first-line treatment of adult patients with advanced renal cell carcinoma |
| Company | Merck-Pfizer |
| BNF chapter | Malignant disease & immunosuppression |
| Assessment type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 10/10/2019 |
| NICE guidance | TA645: Avelumab with axitinib for untreated advanced renal cell carcinoma |